Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

JACC Advances 2026 Open access

Read full text
Authors: Alexander T. Sandhu, Adam Furst, Fátima Elizondo Rodríguez, Neil Kalwani, David Maron, Shriram Nallamshetty, Natasha Din, Kimberly Zitko, Kat Khachatourian, Jeffrey R. Skaar, Ivy Q. Tonnu-Mihara
DOI: 10.1016/j.jacadv.2026.102765
Cited by: 1
References: 45

Abstract

BACKGROUND: Systemic inflammation (SI), measured by high-sensitivity C-reactive protein (hsCRP), is common in both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). OBJECTIVES: The objectives of the study was to evaluate the association between SI and cardiovascular and economic outcomes among Veterans with ASCVD and CKD. METHODS: We conducted an analysis of Veterans with ASCVD and CKD with hsCRP testing between 2008 and 2022. We classified Veterans as with SI (hsCRP 2-10 mg/L) and without SI (hsCRP

Fields of Study & Subjects

Inflammasome and immune disorders Inflammatory Biomarkers in Disease Prognosis Adipokines Inflammation and Metabolic Diseases

Publication details

Journal / source
JACC Advances
Publisher
Elsevier BV
Volume
5
Issue
5
Pages
102765–102765
Publication date
22 April 2026
Language
EN